Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Clinical trial NCT03029403 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03029403
- Sponsor
- University Health Network, Toronto
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-12
- Primary completion
- 2025-12-12
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.